Cardinal Health: A Dividend Aristocrat the Risk Is Already Priced In-Part 2 of 7
|
|
- Godwin Brooks
- 6 years ago
- Views:
Transcription
1 Cardinal Health: A Dividend Aristocrat the Risk Is Already Priced In-Part 2 of 7 November 27, 2017 by Chuck Carnevale of F.A.S.T. Graphs As a value investor, I am totally cognizant of the reality that attractively valued bargains are hard to find in a strong bull market. Moreover, as an experienced value investor I clearly understand that low valuations in a raging bull market are usually associated with issues and challenges sometimes real, sometimes imaginary. The key to success is to identify when current problems are temporary, thereby creating long-term opportunity. With that said, there are a couple of other aspects of value investing that need to be recognized and understood. As a committed value investor, I will never invest in a stock unless I consider it attractively valued. With extremely high quality companies this can simply mean that valuation needs to be sound or reasonable. With less-than-stellar companies, valuations need to be extremely low to be of interest. Nevertheless, I will never knowingly overpay for even the best of businesses. On the other hand, just because a company is fairly valued doesn t automatically make it investment worthy. My point being that although attractive valuation is a critically important investment consideration, it is not the only consideration. From this perspective, valuation is primarily a risk assessment metric more than it is a return assessment. Furthermore, I believe that a comprehensive and thorough research and due diligence effort should be conducted before ever investing in any common stock. However, that requires time and effort on the part of the investor. Consequently, I will not waste my time or take this important step unless I believe that valuation is attractive enough before I start. To me, as a committed value investor, there is little that is more frustrating than getting all excited about a possible stock investment only to determine that its current valuation is excessive. Unfortunately, it is hard to find attractively valued best-of-breed stock investments when markets are high like they are today. Unless, of course, the company is faced with issues that Mr. Market is concerned about. On the other hand, there is nothing a value investor likes better than finding a great business that the market is punishing unjustly. Finding a great business that is undervalued is value investing nirvana. In his 1994 annual report Warren Buffett stated this succinctly as follows: Indeed, we have usually made our best purchases when apprehensions about some macro event were at a peak. Fear is the foe of the faddist, but the friend of the fundamentalist. Page 1, 2018 Advisor Perspectives, Inc. All rights reserved.
2 To summarize this introduction, finding a great business on sale is a fundamental objective of value investing. However, investing in stocks that meet your specific investment objective is also a sound fundamental practice. In other words, a great stock can be discovered at an attractive valuation and still not be appropriate for your portfolio. For example, you might ignore or reject a non-dividend paying growth stock at attractive value because your investment objective is income. This represents another situation where just because a stock is available at an attractive valuation doesn t necessarily imply that it s a good fit for your portfolio. Cardinal Health: A Great Business On Sale? As I have matured, my investment objective has evolved from attempting to achieve maximum total long-term returns to achieving a reliable and growing dividend income stream to supplement my income. Consequently, I am actively looking for attractively valued dividend growth stocks offering dividend yields of 3% or better. This 3% dividend yield goal is not arbitrary. For starters, 3% is an above market dividend yield, and secondarily, a yield level that exceeds my income needs. Therefore, my dividend income meets my needs without ever having to harvest principle (shares). This solidifies the opportunity to receive more dividend income through future dividend increases. Moreover, as stock values have become more and more extended, especially on the majority of highquality dividend growth stocks (such as Aristocrats and Champions), finding attractively valued bluechip dividend growth stocks offering yields of 3% or better has become very challenging. In markets like we have today, there is usually a negative catalyst or catalysts associated with attractive valuations. As previously stated, the trick is to find companies that are either being misappraised by the market, or when the market is overreacting to the negative catalysts. Cardinal Health Inc. (CAH) is a Dividend Aristocrat that has increased its dividend for 32 consecutive years and is currently yielding 3.3%. But perhaps most importantly, I believe the company is worth in the neighborhood of $75 share and is currently available in the mid-50s. Consequently, I believe it offers the rare combination of above-average and growing current yield with the opportunity to generate above-average capital appreciation over the long run and perhaps the short run as well. To be clear, I believe that Cardinal Health is facing short-term issues that have recently generated weak earnings and cash flows. However, I also believe that the market is currently punishing the company s stock price more than it deserves. Consequently, I suggest that Cardinal Health is an extremely undervalued and therefore attractive Dividend Aristocrat on sale. Furthermore, I do believe the company possesses above-average long-term growth potential. As a result, I would expect aboveaverage longer-term total returns resulting from growth coupled with P/E ratio expansion. But best of all, Cardinal Health meets my current investment objective because it provides an above-average current dividend yield coupled with above-average dividend growth. Additionally, it s also important to point out that my investing strategy and objective is long-term buyand-hold oriented. As a value investor, I understand that purchasing out-of-favor stocks can often lead to disappointing short-term performance. On the other hand, as a value investor I also understand that purchasing out-of-favor stocks can lead to enhanced long-term total returns at reduced levels of risk. In other words, my investment horizon is at a minimum 3 to 5 years (a typical business cycle) and Page 2, 2018 Advisor Perspectives, Inc. All rights reserved.
3 preferably forever. As an experienced value investor, I have learned that it takes time for a business to increase its intrinsic value. Frankly, it s a lot easier to be patient when the business is paying you lavishly while you wait. Cardinal Health: Investment Thesis Once I have identified attractive valuation via FAST Graphs, my next step is to conduct some preliminary research. Therefore, I will look to outside sources such as Morningstar and/or Zacks to see what they have to say about the company. Morningstar analyst Vishnu Lekraj in an analyst note on November 6, 2017 stated that Cardinal is one of the most critical players along the pharmaceutical supply chain. The following excerpts provide additional insights into Morningstar s view of Cardinal Health: While the firm s results for the quarter were not stellar, we don t believe they reflect the wholesaler s long-term position. Accordingly, we are reiterating our wide moat rating and $84 fair value estimate for Cardinal. Pressuring the firm s core pharmaceutical segment was a resetting of its generic portfolio pricing. Over the last year, many independent pharmacy clients have demanded lower generic pricing from their respective pharmaceutical wholesalers and Cardinal s two main rivals (Amerisource and McKesson) have had to reprice a material portion of their group purchasing contracts as a result. We believe there has been somewhat of a lag of this trend for Cardinal, which is why its results this quarter were below its peers. After acknowledging some of the issues facing Cardinal Health and its competitors, Morningstar highlighted Cardinal Health s wide moat as follows: Out of all the numerous players along the pharmaceutical supply chain, Cardinal stands out as an elite participant. We believe the firm possesses a wide economic moat, as it is able to turn its significant size and market share into key competitive advantages. Cardinal also plays a critical role within the pharmaceutical industry, given that many supply-chain participants depend on its services for streamlined product distribution and procurement. We expect the use of pharmaceuticals to increase over the next several years, which should provide a solid platform for Cardinal s continued success. Cardinal has also made a few strategic moves that we believe will be beneficial over the long term. For one, it signed an agreement with CVS Caremark where the two firms will combine generic sourcing operations. This should allow it an opportunity to enhance profitability, as the combined sourcing entity will be able to garner greater pricing discounts from generic manufacturers. Cardinal is the third-largest pharmaceutical distributor by revenue and is the main supplier to CVS Health s retail pharmacy network. The firm also supplies several large provider GPOs and mass retailers. The razor-thin profitability of these contracts and the enormous amount of capital needed to build a top-tier global drug wholesaling/distribution operation have formed a solid competitive foundation for Cardinal that has largely kept new entrants at bay. Therefore, at this cursory level of research and due diligence, Morningstar corroborates my thesis that Cardinal Health is undervalued. However, Zacks Research also provided additional insights that further Page 3, 2018 Advisor Perspectives, Inc. All rights reserved.
4 corroborate my thesis: Zacks summary: Over the last year, Cardinal Health has underperformed the broader industry with respect to price. Increasing generic pricing pressure is a major headwind. Intensifying competition and customer concentration are other bottlenecks. A sluggish macroeconomic scenario and tough product pricing environment are likely to impede growth. Meanwhile, the company is banking on strategic buyouts, joint ventures and supply agreements to drive growth. A solid fiscal 2018 guidance instills our confidence in the stock. Also, Cardinal Health ended first-quarter on a solid note, courtesy of an encouraging performance at the Medical segment. Although, the Pharmaceutical segment witnessed strong growth in the Specialty business and gained a huge number of Pharmaceutical Distribution customers, profits at the segment were hurt by generic pharmaceutical pricing and the loss of a major Pharmaceutical Distribution customer. As is Zacks custom in their research reports they also offer reasons to buy and reasons to sell as follows: Reasons to Buy: Acquisition Drives Growth: Cardinal Health follows an acquisition-driven strategy and continues to focus on investment in key growth businesses to gain market traction and boost profits. Cardinal Health announced that it has completed the acquisition of Medtronic s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1 billion. The Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business operates across 23 product categories in multiple market sites of care, like industry-leading brands of Curity, Kendall, Dover, Argyle and Kangaroo brands used in nearly every U.S. hospital. Cardinal Health expects the acquisition to be accretive to adjusted earnings by more than $0.21 per share in fiscal The company has recently entered into an agreement to buy the radioactive diagnostic drug Lymphoseek from Navidea Biopharmaceuticals. In fact over the last five years, the company has spent approximately $5.7 billion on acquisitions of the likes of Cordis (2015), The Harvard Group (2015), AccessClosure (2014), AssuraMed (2013), Kinray (2010), Cardinal Health China (2010) and Healthcare Solutions Holding (2010). These have considerably boosted the company s offerings in diversified fields. The Cordis takeover will expand the company s global footprint over the long haul. Cordis along with AccessClosure will boost the company s portfolio of self-manufactured products under the Medical segment. The Harvard Group deal not only expands Cardinal Health s product portfolio but also its existing telesales programs and capabilities. We believe the company will continue to pursue acquisitions which are strategic fits and will also diversify its revenue base over the long term. Cushioned Against Macroeconomic Sluggishness: Large-cap, diversified healthcare distributors such as Cardinal Health are relatively insulated from macro economic uncertainty and a weak economy. Cardinal Health is one of the largest distributors of pharmaceuticals and medical supplies. It has a diversified product portfolio, which is a hedge against the risk of sales shortfall in testing times. Page 4, 2018 Advisor Perspectives, Inc. All rights reserved.
5 The company s generics business continues to show healthy growth, supported by a solid customer base, significant scale of operation and the competence to source products from a complex and global supply network. Cardinal Health has rationalized the number of generic suppliers. In addition, the company has expanded relationships with generic manufacturers that include several benefits like higher service levels, greater clarity on generic cost of goods sold, and a more consistent product supply with fewer disruptions. Long-term Supply Agreements Buoys Optimism: Cardinal Health is also pursuing growth via joint ventures and long-term supply agreements with several firms. The company entered a long-term strategic agreement with Henry Schein in 2014, under which the latter will purchase Cardinal Health s medical supplies for physician practices. The collaboration is expected to drive core sales and prove accretive to Cardinal Health s earnings in the long term. The signing of a 15-year agreement with Bayer Healthcare for the contract manufacturing of Xofigo is significantly positive. In our opinion, this will help the company leverage its expertise in the nuclear pharmacy industry to expand access to a therapeutic agent and increase the use of radiopharmaceuticals in the U.S. and Canada. The Red Oak Sourcing joint venture with CVS Health, which will negotiate generic pharmaceutical supply contracts on behalf of both companies, also holds significant long-term prospects for Cardinal Health. Good Client Retention: The performance of Cardinal Health s Pharmaceutical segment has been facilitated by good client retention, with the loss of only a few key customers (Walgreens and Express Scripts). Cardinal Health has already renewed many of its chain customer contracts for subsequent years. The concentration of suppliers has also been well managed by the company. Strong Balance Sheet: Cardinal Health s strong balance sheet and cash flow enable it to pursue growth opportunities and accretive acquisitions. The company uses its cash flow to return value to investors in the form of dividends and share repurchases. In fiscal 2017, the company returned more than $1.2 billion to shareholders through stock repurchases and dividend payouts. Aggressive share buybacks will boost earnings as well as shareholders value over the long run. In fiscal 2017, operating cash flow at the company was $1.2 billion, of which $387 million was deployed in capital expenditures. Reasons to Sell: Share price movement: Cardinal Health stock price has significantly underperformed thus far in Probabilities of Loss of a Major Customer Worrisome: Collectively, 5 of Cardinal Health s main customers, including CVS, accounted for as much as 40% of its revenues. Group Purchasing Organizations: Cardinal Health derives a significant quantum of revenues through agreements with group purchasing organizations (GPO s). The company s largest GPO agents are Asembia, HealthTrust, Innovatix,Intalere, Premier Purchasing Partners and 6 others. Loss of any of these agents with severely affect the company sells. Integration Risks: Cardinal Health continues to acquire a large number of companies. This improves revenue but also adds integration risk. Page 5, 2018 Advisor Perspectives, Inc. All rights reserved.
6 Cutthroat Competition in Niche Space: Cardinal Health faces tough competition in each of its business segments. By screening the Standard & Poor s Dividend Aristocrats via FAST Graphs looking for attractive value, Cardinal Health was one of only 7 Dividend Aristocrats that appeared reasonably valued. After reviewing research from Morningstar and Zacks I concluded that Cardinal Health was a stock worthy of conducting a more comprehensive research and due diligence process on. Consequently, my next step is to run it through a comprehensive fundamental valuation analysis utilizing the numerous earnings and cash flow metrics available FAST Graphs. Cardinal Health Inc.: FAST Graphs Analyze Out Loud Valuation Analysis The following analyze out loud video will present a quick overview of Cardinal Health Inc. based primarily on price relative to earnings and cash flow. However, as discussed above, I will also evaluate several other metrics. For any reader concerned with the current valuation of Cardinal Health Inc., this video is a must watch. Furthermore, although I will be only providing a cursory, or a pre-more comprehensive due diligence analysis, I believe you will find the video enlightening and hopefully entertaining. Summary and Conclusions Cardinal Health is a powerhouse in its respective industry. It is the second-largest by market and thirdlargest by revenues and one of three major pharmaceutical distributors in the US. Yes, it s true that the company and in fact its entire industry is currently out-of-favor with Mr. Market. Nevertheless, the following slide from Cardinal Health s recent annual meeting of shareholders on November 8, 2017 summarizes the breadth and depth of Cardinal Health s business: Page 6, 2018 Advisor Perspectives, Inc. All rights reserved.
7 Although there is certainly a significant amount of perceived risks associated with investing in Cardinal Health or the pharmaceutical distribution industry in general, I believe that the risks are already reflected in the price. Cardinal Health is aware of the changing healthcare landscape and is taking steps to maintain their relevance and profitability. The following slide depicts Cardinal Health s commitment to shareholders and to continuing to support future growth: Page 7, 2018 Advisor Perspectives, Inc. All rights reserved.
8 In conclusion, I believe that Cardinal Health represents an intriguing investment opportunity given the state of today s stock market. The company and its entire industry are currently out-of-favor with the market. However, I contend that Cardinal Health s low valuation mitigates much of the risk associated with investing in it while simultaneously provides the opportunity for enhanced long-term returns. Consequently, whether your investment objective is high current income and dividend growth or aboveaverage total returns Cardinal Health might deserve a closer look. Disclosure: Long CAH at the time of writing. Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation. Page 8, 2018 Advisor Perspectives, Inc. All rights reserved.
9 F.A.S.T. Graphs Page 9, 2018 Advisor Perspectives, Inc. All rights reserved.
Campbell Soup Company: High-Yield and Speculative Capital Gain Potential-Part 4
Campbell Soup Company: High-Yield and Speculative Capital Gain Potential-Part 4 June 7, 2018 by Chuck Carnevale of F.A.S.T. Graphs This is the fourth of what will be a long-running series highlighting
More informationDesigning a Retirement Portfolio That s Just Right For You
Designing a Retirement Portfolio That s Just Right For You July 10, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction No one knows your own personal financial situation better than you do. Every
More informationEmerson Electric: High-yield, Sound Valuation and 59 Consecutive Years of Dividend Increases, Part 2
Emerson Electric: High-yield, Sound Valuation and 59 Consecutive Years of Dividend Increases, Part 2 May 27, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction When I m looking for a stock to add
More information10 Attractive Dividend Growth Stocks Poised to Become the Next Dividend Champions Or Aristocrats
10 Attractive Dividend Growth Stocks Poised to Become the Next Dividend Champions Or Aristocrats January 12, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction I screened the Dividend Contenders list
More information7 Intriguing Healthcare Growth Stocks in the S&P 500: Part 2
7 Intriguing Healthcare Growth Stocks in the S&P 500: Part 2 August 15, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction The S&P 500 index is commonly used as a benchmark that investors use to measure
More informationThese Are the Only Dividend Aristocrats I Would Consider Today
These Are the Only Dividend Aristocrats I Would Consider Today July 8, 2016 by Chuck Carnevale of F.A.S.T. Graphs Generally speaking, the overall stock market is fully valued at best, and in many cases
More informationWhat Will Happen To the Stock Market When Interest Rates Rise? Part 1
What Will Happen To the Stock Market When Interest Rates Rise? Part 1 July 21, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction Interest rates have been in a freefall for the better part of the
More informationDon t Be a Stock Market Victim!
Don t Be a Stock Market Victim! December 27, 2018 by Chuck Carnevale of F.A.S.T. Graphs Introduction The primary objective of this article is to help the reader put this recent bad market in perspective
More informationCardinal Health Reports Third-quarter Results for Fiscal Year 2017
Exhibit 99.1 FOR IMMEDIATE RELEASE Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Third-quarter
More informationThe Threat and Risk of Rising Interest Rates: Separating Fact from Fiction
The Threat and Risk of Rising Interest Rates: Separating Fact from Fiction March 24, 2017 by Chuck Carnevale of F.A.S.T. Graphs Introduction The threat of rising interest rates is all the rage in financial
More informationInvest In Walgreens Or CVS Speculate In Rite Aid
Invest In Walgreens Or CVS Speculate In Rite Aid January 23, 2018 by Chuck Carnevale of F.A.S.T. Graphs Introduction For many years now, investing in healthcare related stocks has presented me with a conundrum
More informationCelgene: A Primer on Growth Stock Value Investing (GARP): Part 2
Celgene: A Primer on Growth Stock Value Investing (GARP): Part 2 November 13, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction This article is the second in a two-part series on applying the principles
More information10 Dividend Growth Stocks for Your Retirement Portfolios Aggregate Yield 4.3%: Part 2
10 Dividend Growth Stocks for Your Retirement Portfolios Aggregate Yield 4.3%: Part 2 August 12, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction After an exhaustive search of the dividend growth
More informationDividends True Contribution to Total Return May Surprise You
Dividends True Contribution to Total Return May Surprise You March 30, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction In recent years, dividends contribution to total return has been one of the
More information10 Undervalued Dividend Champions For 2016: Be Greedy When Others Are Fearful
10 Undervalued Dividend Champions For 2016: Be Greedy When Others Are Fearful December 24, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Dividend Champions/Aristocrats are the go-to dividend
More informationIs The Increase In Volatility Signaling A Dangerous Market Environment?
Introduction Is The Increase In Volatility Signaling A Dangerous Market Environment? November 14, 2016 by Chuck Carnevale of F.A.S.T. Graphs Over the last several weeks stock price volatility has increased
More informationPeter Lynch Taught Me to Invest in Ultra Beauty Inc.
Introduction Peter Lynch Taught Me to Invest in Ultra Beauty Inc. February 1, 2018 by Chuck Carnevale of F.A.S.T. Graphs In his best-selling book One up on Wall Street Peter Lynch included this subtitle
More information20 Dividend Growth Stocks To Buy Today For Your Retirement Portfolios: Part 1
20 Dividend Growth Stocks To Buy Today For Your Retirement Portfolios: Part 1 August 7, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction We are in the seventh year of a strong bull market, and stock
More informationDesigning a Dividend Growth Portfolio for a Specific Retirement Yield Objective: Part 1
Designing a Dividend Growth Portfolio for a Specific Retirement Yield Objective: Part 1 October 2, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Managing an investment portfolio is a very personal
More informationHow to Forecast Future Stock Returns: Part 3
How to Forecast Future Stock Returns: Part 3 Chuck Carnevale - Monday, July 16, 2012 Introduction In Part 1 and Part 2 of this three-part series, we established the basic principles of valuation and provided
More informationDelivering Value for All Health Care Stakeholders. Larry Merlo President & Chief Executive Officer
Delivering Value for All Health Care Stakeholders Larry Merlo President & Chief Executive Officer Agenda Our Value Proposition Has Never Been Stronger We See Compelling Opportunities in a Robust Health
More informationTestimony of Sherrill Neff, Quaker BioVentures for the Joint Economic Committee of Congress July 10, 2008
Testimony of Sherrill Neff, Quaker BioVentures for the Joint Economic Committee of Congress July 10, 2008 Introduction: Members of the Committee, good morning. My name is Sherrill Neff and I am a partner
More informationStock Selection Options by Category: Part 2A
Stock Selection Options by Category: Part 2A October 31, 2018 by Chuck Carnevale of F.A.S.T. Graphs Introduction In part 1 of this series titled How Many Stocks Should I Own? found here, I focused primarily
More informationj2 Global: Don t Overlook This Impressive Growth and Dividend Income Stock
j2 Global: Don t Overlook This Impressive Growth and Dividend Income Stock March 3, 2017 by Chuck Carnevale of F.A.S.T. Graphs j2 Global (JCOM) was founded in 1995 and went public in 1999. During their
More informationFossil Inc Fundamental Stock Research Analysis
Fossil Inc Fundamental Stock Research Analysis January 22, 2013 by Team of F.A.S.T. Graphs Growth stocks are defined as companies with high rates of change of earnings growth of 15% to 20% or better. Growth
More informationSocial Reality, Inc. (Stock Symbol Nasdaq: SRAX) Prepared By: David L. Lavigne
Earnings Update 2Q F2017 Report Date: 08/21/2017 12-24 month Price Target: $7.50 Allocation: 5 Closing Stock Price at Initiation (Close 04/24/17): $1.90 Closing Stock Price at Update (Close 08/21/17):
More informationThe Great Beta Hoax: Not an Accurate Measure of Risk After All
The Great Beta Hoax: Not an Accurate Measure of Risk After All May 21, 2015 by Chuck Carnevale of F.A.S.T. Graphs Every investor is concerned with risk at some level. Arguably investors in retirement are
More informationWhich Is the Better Valuation Metric? The P/E Ratio or the PEG Ratio: Part 1
Which Is the Better Valuation Metric? The P/E Ratio or the PEG Ratio: Part 1 October 28, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction Recently, I have been engaged in rather intense discussions
More informationALPHAWEALTH PRIME SMALL & MID CAP FUND COMMENTARY MONTH OF NOVEMBER December 2018
ALPHAWEALTH PRIME SMALL & MID CAP FUND COMMENTARY MONTH OF NOVEMBER 2018 3 December 2018 AlphaWealth (Pty) Ltd. Reg. No.: 2004/026495. An authorised financial services provider - FSP Licence No. 13808.
More informationEnhanced Investment Perspectives
Practices > Management Consulting Enhanced Investment Perspectives We have served as a trusted advisor across the asset landscape and investment lifecycle on the strategic implications of pursuing investment
More information2009 UBS Healthcare Services Conference
2009 UBS Healthcare Services Conference February 10, 2009 John H. Hammergren Chairman and Chief Executive Officer Safe Harbor Clause Some of the information in this presentation may constitute forwardlooking
More informationHope Is Not A Strategy, Before Investing Have A Precise Calculation Of Return In Mind
Hope Is Not A Strategy, Before Investing Have A Precise Calculation Of Return In Mind May 2, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Many people make the mistake of investing in a stock
More informationWashington,D.C Form8-K. CurrentReport. May1,2017 DateofReport. (Dateofearliesteventreported)
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 Form8-K CurrentReport PursuanttoSection13or15(d)ofthe SecuritiesExchangeActof1934 May1,2017 DateofReport (Dateofearliesteventreported)
More informationInvestment Management Philosophy
Investment Management Philosophy Executive Overview The investment marketplace has grown increasingly complex and unpredictable for individual investors. This reality may make it difficult for many people
More informationDividends Don t Drive Total Return They Contribute To It: Part 1
Dividends Don t Drive Total Return They Contribute To It: Part 1 March 3, 2016 by Chuck Carnevale of F.A.S.T. Graphs I believe there is a critical piece of investment wisdom that all investors in common
More informationThe Math of Intrinsic Value
The Math of Intrinsic Value Introduction: In India and across the world, the most commonly found investment options are bank fixed deposits, gold, real estate, bonds and stocks. Since over a hundred years
More informationDiversified Stock Income Plan
Joseph E. Buffa, Equity Sector Analyst Michael A. Colón, Equity Sector Analyst Diversified Stock Income Plan 2017 Concept Review The Diversified Stock Income Plan (DSIP List) focuses on companies that
More informationTempleton China Fund
Franklin Templeton Investment Funds Templeton China Fund Core Value Fund Profile Fund Details Inception Date 1 September 1994 Investment Style Benchmark(s) Core Value MSCI Golden Dragon Index FUND OBJECTIVE
More informationINTRINSIC VALUE ASSESSMENT OF GILEAD SCIENCES (GILD) Introduction. The Intrinsic Value of Gilead Sciences
JANUARY 1, 2018 This article was written with David J. Flood from The Investor s Podcast Introduction Gilead Sciences is an American based Biopharmaceutical corporation whose principal business involves
More informationBCA 4Q 2018 Review and 2019 Outlook Russ Allen, CIO. Summary Outlook
BCA 4Q 2018 Review and 2019 Outlook Russ Allen, CIO Summary Outlook January 15, 2019 Markets in 2019 will be choppy with volatility more like this past year than the placid trading of 2017. The Fed is
More informationFinding Great Value In The Energy Sector
Finding Great Value In The Energy Sector June 21, 2013 by Chuck Carnevale of F.A.S.T. Graphs This will be the second in a series of articles designed to find value in today s stock market environment.
More informationIN A TOUGH MARKET, INVESTORS SEEK NEW WAYS TO CREATE VALUE
IN A TOUGH MARKET, INVESTORS SEEK NEW WAYS TO CREATE VALUE By Julien Ghesquieres, Jeffrey Kotzen, Tim Nolan, and Hady Farag This article is the second in the 6 BCG Value Creators series. In May 6, we released
More informationCommand Center, Inc.
Earnings Update: Q3-Fiscal 2017 Report Date: 11/15/17 12-24 month Price Target: $.80 Allocation: 4 Closing Stock Price at Initiation (Close 09/08/17): $.37 Closing Stock Price (Close 11/14/17): $.46 Command
More informationQ Formulary Performance:
Insights Executive Briefing Issue 10, 2016 Q1 2016 Performance: Key Data to Consider as You Look Ahead to 2017 Increasingly our clients see proactive, dynamic formulary management as a necessary response
More informationFirst Pacific Advisors, LLC
FPA U.S. Value Fund, Inc. (FPPFX) Fourth Quarter 2016 Webcast Presented by: Gregory Nathan FPA U.S. Value Fund, Inc. Q4 2016 Summary Summary: Continual lack of widespread value throughout the market However,
More informationBONHOEFFER CAPITAL MANAGEMENT
BONHOEFFER CAPITAL MANAGEMENT Dear Partner, Welcome to the Bonhoeffer Fund, LP. As the fund manager, I want to humbly thank you for entrusting me with the responsibility of investing and growing your hard-earned
More informationCVS HEALTH/AETNA INVESTOR CALL SCRIPT
MIKE McGUIRE, CVS HEALTH IRO Good morning, everyone. Thanks so much for joining us this morning to hear about the definitive merger agreement we announced yesterday to acquire Aetna, one of the nation
More informationGoldman Sachs Presentation to Bernstein Strategic Decisions Conference
Goldman Sachs Presentation to Bernstein Strategic Decisions Conference Comments by Gary Cohn, President and Chief Operating Officer May 31, 2012 Slide 2 Thanks Brad, good morning to everyone. Slide 3 In
More informationSocial Reality, Inc. (Stock Symbol Nasdaq: SRAX)
Initiating Research Coverage Report Date: 05/22/2017 12-24 month Price Target: $7.50 Allocation: 4 Closing Stock Price at Initiation (Close 04/24/17): $1.90 Closing Stock Price at Update (Close 05/22/17):
More informationInvestor Presentations
Investor Presentations A company s investor presentation serves as a leading source of information for institutional money managers and is a vital tool to engage with investors. Companies should be acutely
More informationRetired Investors: Apply a Value Investing Strategy and Earn More Income and Higher Returns
Retired Investors: Apply a Value Investing Strategy and Earn More Income and Higher Returns November 10, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Value investing produces safe, powerful
More informationCardinal Health Reports Second-quarter Results for Fiscal Year 2018
FOR IMMEDIATE RELEASE Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Second-quarter Results
More informationGrowth and Value Investing: A Complementary Approach
Growth and Value Investing: A Complementary Approach March 14, 2018 by Stephen Dover, Norman Boersma of Franklin Templeton Investments Growth and value investing are often seen as competing styles, with
More informationInterview With John Khabbaz of Phoenician Capital
Interview With John Khabbaz of Phoenician Capital Interview With John Khabbaz of Phoenician Capital To start off, can you tell us a bit about Phoenician Capital and the team working at the fund? Phoenician
More informationAnalyst's Notes. Argus Recommendations
Report created Jan 17, 2018 Page 1 OF 5 Citigroup is one of world's largest banks, with global consumer banking, corporate banking, and investment banking operations. Of the largest U.S. banks, Citigroup
More informationTempleton Emerging Markets Smaller Companies Fund
Franklin Templeton Investment Funds Templeton Emerging Markets Smaller Companies Fund Core Value Fund Profile Fund Details Inception Date 18 October 2007 Investment Style Benchmark(s) Core Value MSCI Emerging
More informationThe (Un)Reliability of Past Performance
The (Un)Reliability of Past Performance The longer your view, the better your perspective By Baird s Advisory Services Research If you re making investment decisions with the assumption that recent performance
More informationFirst REIT. First-Rate Performance S$1.100 S$ Intrinsic Value Prev Closing. 27 April
First REIT First-Rate Performance Increase Exposure Intrinsic Value Prev Closing S$1.100 S$0.880 Update: First REIT ( Company ) announced its financial year 2010 first quarter results on 23 rd April 2010.
More informationPerspectives On 2004 and Beyond Ron Surz, President, PPCA, Inc.
Volume 8, No. 1 Senior Consultant The Voice of the Investment Management Consultant Perspectives On 24 and Beyond Ron Surz, President, PPCA, Inc. Due to a 4th quarter rally, the stock market returned 12%
More informationRISK MANAGEMENT DUE DILIGENCE FOR MERGERS & ACQUISITIONS
DUE DILIGENCE due dil i gence noun Research and analysis of a company or organization done in preparation for a business transaction, particularly for mergers and acquisitions. RISK MANAGEMENT DUE DILIGENCE
More informationValueWalk Interview With Chris Abraham Of CVA Investment Management
ValueWalk Interview With Chris Abraham Of CVA Investment Management ValueWalk Interview With Chris Abraham Of CVA Investment Management Rupert Hargreaves: You run a unique, value-based options strategy
More informationTempleton Emerging Markets Fund
Franklin Templeton Investment Funds Templeton Emerging Markets Fund Core Value Fund Profile Fund Details Inception Date 28 February 1991 Investment Style Benchmark(s) Core Value MSCI Emerging Markets Index
More informationTempleton Africa Fund
Franklin Templeton Investment Funds Templeton Africa Fund Core Value Fund Profile Fund Details Inception Date 4 May 2012 Investment Style Benchmark(s) Core Value Dow Jones Titans Africa 50 Index FUND OBJECTIVE
More informationArtisan Partners U.S. Value Team
Artisan Partners U.S. Value Team Investment Philosophy and Process Artisan Value Fund Artisan Mid Cap Value Fund We seek cash-producing businesses in strong financial condition that are selling at undemanding
More informationWhen is the PEG Ratio Superior to the P/E Ratio? Part 2
When is the PEG Ratio Superior to the P/E Ratio? Part 2 November 3, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction Financial metrics such as P/E ratios, price to cash flow ratios, PEG ratios,
More informationACTIVIST INVESTING RESEARCH
106 Yeakel Avenue Erdenheim, PA 19038 Damien J. Park President & CEO dpark@hedgerelations.com T: 215.325.0514 F: 215.392.4633 ACTIVIST INVESTING RESEARCH Company: Endo Pharmaceuticals Holdings, Inc. (ENDO)
More information2016 July Financial Market Update
Brexit Fades as Focus Returns Home 2016 July Financial Market Update Last month s summary ended with the following remarks: July 29, 2016 Don t discount the possibility of additional short-term volatility
More informationDENTSPLY International Inc.
March 18, 2015 DENTSPLY International Inc. Current Recommendation Prior Recommendation NEUTRAL Outperform Date of Last Change 02/19/2012 Current Price (03/17/15) $51.13 Target Price $54.00 SUMMARY (XRAY-NASDAQ)
More informationFranklin European Growth Fund
Franklin Templeton Investment Funds Franklin European Growth Fund Flex-Cap Growth Fund Profile Fund Details Inception Date 29 December 2000 Investment Style Flex-Cap Growth Benchmark(s) MSCI Europe Index
More informationEquity Research. Beacon Roofing Supply, Inc. (BECN-NSDQ) OUTLOOK SUMMARY DATA ZACKS ESTIMATES. Hold Prior Recommendation. Current Recommendation
Equity Research July 7, 2006 Mario Ricchio www.zacks.com 155 North Wacker Drive Chicago, IL 60606 Beacon Roofing Supply, Inc. (BECN-NSDQ) Current Recommendation Hold Prior Recommendation Buy Date of Last
More informationIn Today s Overheated Market Control Risk in Your Retirement Portfolios with Sound Valuation
In Today s Overheated Market Control Risk in Your Retirement Portfolios with Sound Valuation August 21, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Investing money in anything is never without
More informationInvest with Confidence: The Five Laws of Building Wealth through Real Estate
Invest with Confidence: The Five Laws of Building Wealth through Real Estate Are you financially prepared for retirement? Do you know how true wealth is generated? IN FACT, IN THE U.S., 80% OF NON-HOME
More informationGlobal Equity Fund Money Manager and Russell Investments Overview January 2018
Money Manager and Russell Investments Overview January 2018 RUSSELL INVESTMENTS APPROACH Russell Investments uses a multi-asset approach to investing, combining asset allocation, manager selection and
More informationThe Truth About Top-Performing Money Managers
The Truth About Top-Performing Money Managers Why investors should expect and accept periods of poor relative performance By Baird s Advisory Services Research Executive Summary It s only natural for investors
More informationUnitedHealth Group Fourth Quarter and Year End 2014 Results Teleconference Prepared Remarks January 21, Moderator:
UnitedHealth Group Fourth Quarter and Year End 2014 Results Teleconference Prepared Remarks January 21, 2015 Moderator: Good morning, I will be your conference facilitator today. Welcome to the UnitedHealth
More informationROYAL BANK OF CANADA FIRST QUARTER RESULTS CONFERENCE CALL WEDNESDAY, FEBRUARY 25, 2015
ROYAL BANK OF CANADA FIRST QUARTER RESULTS CONFERENCE CALL WEDNESDAY, FEBRUARY 25, 2015 DISCLAIMER THE FOLLOWING SPEAKERS NOTES, IN ADDITION TO THE WEBCAST AND THE ACCOMPANYING PRESENTATION MATERIALS,
More informationFranklin European Dividend Fund
Franklin Templeton Investment Funds Franklin European Dividend Fund Flex-Cap Blend Fund Profile Fund Details Inception Date 29 July 2011 Investment Style Flex-Cap Blend Benchmark(s) MSCI Europe Index Fund
More informationFranklin European Growth Fund
Franklin Templeton Investment Funds Franklin European Growth Fund Flex-Cap Growth Fund Profile Fund Details Inception Date 29 December 2000 Investment Style Flex-Cap Growth Benchmark(s) MSCI Europe Index
More informationCHAPTER 2. Capital Structure and Debt Capacity. Balancing Operating / Business Risk and Financial Risk
CHAPTER 2 Capital Structure and Debt Capacity Balancing Operating / Business Risk and Financial Risk A company s capital structure is comprised of a combination of debt and equity that is used to fund
More informationSEATTLE S BEST COFFEE? Using ZRS and the Zacks Valuation Model to identify factors impacting equity valuations in 3 minutes or less
Using ZRS and the Zacks Valuation Model to identify factors impacting equity valuations in 3 minutes or less SEATTLE S BEST COFFEE? Starbucks: Can this International coffeehouse add value to your portfolio?
More informationFranklin European Growth Fund
Franklin Templeton Investment Funds Franklin European Growth Fund Flex-Cap Growth Fund Profile Fund Details Inception Date 29 December 2000 Investment Style Flex-Cap Growth Benchmark(s) MSCI Europe Index
More informationCardinal Health, Inc. Earnings Investor/Analyst call May 1, 2017
Q3 FY2017 Cardinal Health, Inc. Earnings Investor/Analyst call May 1, 2017 Copyright 2017, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved Forward-looking statements and GAAP reconciliation
More informationGoldman Sachs Presentation to Bernstein Strategic Decisions Conference
Goldman Sachs Presentation to Bernstein Strategic Decisions Conference Comments by Gary Cohn, President and Chief Operating Officer May 30, 2013 Slide 1 Thanks Brad, and good morning to everyone. The operating
More informationDesigning the Appropriate Common Stock Retirement Portfolio: Stock Selection Options Part 1
Designing the Appropriate Common Stock Retirement Portfolio: Stock Selection Options Part 1 September 14, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction What is the best way to design or construct
More informationSUMMARY. Risk Level *
January 09, 2015 Fred s Inc (FRED-NASDAQ) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Underperform Date of Last Change 07/17/2014 Current Price (01/08/15) $17.13 Target Price $18.00
More informationSchroder US Small Cap Equity
Schroder US Small Cap Equity Strategy Overview Summary Firm highlights The Schroder US Small Cap Equity Strategy is a bottom-up, fundamental and researchbased approach. The portfolio manager and analysts
More informationIntroduction Forest Avenue, Suite 130 Chico, CA PH:
Introduction Pinyon Pine Capital (PPC) is a registered investment advisory firm that began managing client accounts in March of 2011. The firm has three investment strategies: long-only, highly concentrated
More informationFourth-quarter revenue increased 7 percent to $35 billion; full-year revenue increased 5 percent to $137 billion
Exhibit 99.1 FOR IMMEDIATE RELEASE Media: Ellen Barry Investors: Lisa Capodici (614) 553-3858 (614) 757-5035 ellen.barry@cardinalhealth.com lisa.capodici@cardinalhealth.com Cardinal Health Reports Fourth-quarter
More informationHealthcare is changing We re changing healthcare. George S. Barrett Chairman and Chief Executive Officer
Healthcare is changing We re changing healthcare. George S. Barrett Chairman and Chief Executive Officer 25th Annual Credit Suisse Healthcare Conference Tuesday, November 8th Copyright 2016, Cardinal Health,
More informationPicking and valuing stocks: The BIG way. Amy Ran, Ben Eisenberg, and Conor O Gorman
Picking and valuing stocks: The BIG way Amy Ran, Ben Eisenberg, and Conor O Gorman The Theory of Competition Recall from Econ 1: Under perfect competition in the long run, the economic profit of a firm
More informationU.S. Stocks: Can We Capture Acceptable Returns From Here?
March 2015 For discretionary use by investment professionals. U.S. Stocks: Can We Capture Acceptable Returns From Here? Editor s Note: The following commentary was written by Litman Gregory co founder
More informationSUN LIFE MULTI-STRATEGY TARGET RETURN FUND
SUN LIFE MULTI-STRATEGY TARGET RETURN FUND Aims to deliver long-term capital growth regardless of market conditions I N S T I T U T I O N A L TABLE OF CONTENTS 02 FOCUSING ON INVESTORS 08 MANAGING AND
More informationACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS. Supporting employees and building sustainable drug plans...together
ACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS Supporting employees and building sustainable drug plans...together Not available in the province of Quebec INTRODUCING THE SPECIALTY DRUG PROGRAM If you
More informationA Top-Performing Multi-Asset ESG Income Fund
A Top-Performing Multi-Asset ESG Income Fund July 5, 2016 by Robert Huebscher Eventide Asset Management, LLC is a Boston-based Registered Investment Advisor and serves as the Advisor to Eventide Mutual
More informationEquity Crowdfunding Guide
Equity Crowdfunding Guide FOR ISSUING COMPANIES 1 P a g e Disclaimer: Crowd88 does not provide financial advice. This guide has been prepared as a support document to provide Issuing Companies with a greater
More informationIn the Middle Lies Opportunity: The Case for Mid Caps
In the Middle Lies Opportunity: The Case for Mid Caps Despite their attractive risk and return characteristics, U.S. mid cap stocks are frequently overlooked by equity investors; that may be hurting their
More informationMODEL WEALTH PORTFOLIOS. focus on. your future. LPL Financial Research
focus on your future LPL Financial Research Your Strategic Partner: LPL Financial Research Our Approach Your investment strategist consists of seasoned and accomplished industry veterans, comprising one
More informationThe Truth about Top-Performing Money Managers
The Truth about Top-Performing Money Managers Why investors should expect and accept periods of poor relative performance By Baird s Advisory Services Research Executive Summary It s only natural for investors
More informationWashington,D.C Form8-K. CurrentReport. August2,2017 DateofReport. (Dateofearliesteventreported)
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 Form8-K CurrentReport PursuanttoSection13or15(d)ofthe SecuritiesExchangeActof1934 August2,2017 DateofReport (Dateofearliesteventreported)
More informationWalgreens Boots Alliance Reports Fourth Quarter and Fiscal 2016 Results
20 October 2016 Boots Alliance Reports Fourth Quarter and Fiscal 2016 Results Fourth quarter highlights GAAP diluted net earnings per share increase to $0.95 from $0.02 in the year-ago quarter; Adjusted
More information